Clinical pathway
Overactive Bladder
The EAU 2026 non-neurogenic female overactive-bladder pathway — OAB is a symptom diagnosis, managed up a fixed ladder: assessment and wet/dry classification, conservative and behavioural therapy (including PTNS), pharmacotherapy (antimuscarinic then beta-3 agonist), refractory minimally-invasive third-line (intravesical onabotulinumtoxinA, sacral neuromodulation), last-resort surgery, and early follow-up. Switch between the visual Pathway map and the phase-by-phase Explorer.
LegendKey state / milestoneDecisionLink to phaseStrong recommendationWeak / conditionalNo formal recommendation
Loading pathway…
Study reference — verify against current EAU guidelines before clinical use. Dashed amber = weak recommendation; dashed taupe = no formal recommendation.